Join us November 2-6, 2018 in Paris, France for the Joint Global Neurofibromoatosis Conference, a global event attracting more than 800 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis.
Children's Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD, addressed the attendees at the annual NF Conference Welcome Dinner on Saturday, June 10, 2017 at the National Press Club in Washington, DC. Dr. Bakker spoke to the nearly 400 attendees about the importance of disease-focused research, the advantages of team science, and the development of an infrastructure intended to bring biotech and pharmaceutical companies to the NF table. She highlighted CTF's innovative research model, and its tremendous potential for further application to other rare disease, as well as cancer research. The NF Conference is the premier gathering of scientists and clinicians from around the world dedicated to advancing research and care for those living with NF.
Greg Simon, Director, Biden Cancer Initiative, was the Keynote Speaker at the 2017 NF Conference Welcome Dinner on Saturday, June 10, 2017. The NF Conference is the premier gathering of scientists and clinicians from around the world dedicated to advancing research and care for those living with NF. Mr. Simon addressed the nearly 400 attendees on the topics of research collaboration and breaking down barriers to research progress. Introducing Mr Simon is Annette Bakker, PhD, Children's Tumor Foundation President and Chief Scientific Officer. Click thru to view his presentation.
The second session of the 2017 NF Conference, chaired by Dr. Ludwine Messiaen and Dr. Miriam Smith, focused on the associations between the complex physical manifestations of NF and the diverse genetic variations observed in NF patients. Understanding these ‘genotype-phenotype correlations’ is important for better management of NF and can potentially also pave the way for targeted therapeutic interventions.
The 2017 NF Conference, with nearly 400 researchers and clinicians in attendance (making it the largest NF Conference to date), kicked off on Saturday, June 10th, with stem cell technology as a tool for discovering new NF1 treatments as the topic of a group of thought-provoking talks. Keynote speaker Elaine Fuchs, PhD, a specialist in skin biology, skin stem cells and associated genetic disorders, including cancers, introduced a session on how understanding and influencing these processes can be applied to NF1 skin manifestations and how these cells may hold the key to creating stable cell lines for investigation.